Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice

References

• World Health Organization (WHO). World Health Report 2003 – Shaping the future. World Health Organization 2003: Geneva, Switzerland, 2003
   Google Scholar
• Allender S, Scarborough P, Peto V, et al. European cardiovascular disease statistics 2008. European Heart Network: Brussels, Belgium, 2008
   Google Scholar
• American Heart Association. Heart Disease and Stroke Statistics – 2009 Update. Dallas, TX: American Heart Association, 2009
   Google Scholar
• Graham IM Guidelines on cardiovascular disease prevention in clinical practice: the European perspective. Curr Opin Cardiol 2005;20:430-9
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil 2007;14:S1-113
   PubMed Web of Science ®Google Scholar
• Pearson TA, Bazzarre TL, Daniels SR, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003;107:645-51
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91
   PubMed Web of Science ®Google Scholar
• Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Healthy People 2010: With Understanding and Improving Health and Objectives for Improving Health. Washington, DC: Government Printing Office, 2000
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32
   PubMed Web of Science ®Google Scholar
• Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update of 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107:433-43
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Berne C, Siewert-Delle A, and the URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005;4:7
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Gibson JM, Sager PT Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined c-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007;100:1245-8
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BHR, Franken AAM, Vincent HH on behalf of the Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Int Med 2005;257:531-9
   PubMed Web of Science ®Google Scholar
• Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2003
   Google Scholar
• Lipitor [package insert]. New York, NY: Pfizer Inc, 2004
   Google Scholar
• Zocor [package insert]. Whitehouse Station, NJ: Merck & Co, Inc, 2004
   Google Scholar
• Pravachol [package insert]. Princeton, NJ: Bristol-Myers Squibb Co, 2004
   Google Scholar
• Lescol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, 2003
   Google Scholar
• Mevacor [package insert]. Whitehouse Station, NJ: Merck & Co, Inc, 2004
   Google Scholar
• Avorn J. In defense of pharmacoepidemiology – embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-21
   PubMed Web of Science ®Google Scholar
• Ohsfeldt RL, Gandhi SK, Fox KM, et al. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care 2006;12:S412-23
   PubMed Web of Science ®Google Scholar
• Kamat SA, Gandhi SK, Davidson MH Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin 2007;23:1121-30
   PubMed Web of Science ®Google Scholar
• Bullano MF, Kamat S, Wertz DA, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm 2007;64:276-84
   PubMed Web of Science ®Google Scholar
• Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-78
   PubMed Web of Science ®Google Scholar
• Heintjes EM, Hirsch MW, Linden M, et al. LDL-C reductions and goal attainment among naïve statin users in the Netherlands: real life results. Curr Med Res Opin 2008;24:2241-50
   PubMed Web of Science ®Google Scholar
• Harley CR, Gandhi S, Heien H, et al. The comparative effectiveness of rosuvastatin vs. other statins in patients with an increased risk of failure to reach NCEP ATP III goal. Int J Clin Pract 2008;62:889-95
   PubMed Web of Science ®Google Scholar
• Ohsfeldt RL, Gandhi SK, Fox KM, et al. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health 2008;11:1061-9
   PubMed Web of Science ®Google Scholar
• Kassianos G, Reckless J, Emmas C, et al. A UK survey of rosuvastatin in general practice: reaching cholesterol targets. Br J Cardiol 1008;15:95-100
   Google Scholar
• Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-6
   PubMed Web of Science ®Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, et al. Effectiveness of statins in Medicare-eligible patients and patients <65 years using clinical practice data. Int J Clin Pract 2007;61:1634-42
   PubMed Web of Science ®Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, et al. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Cur Med Res Opin 2007;23:2125-33
   PubMed Web of Science ®Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, et al. Comparison of low density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in real-world clinical practice setting. Am J Manag Care 2007;13:S270-5
   PubMed Web of Science ®Google Scholar
• Harley CR, Gandhi S, Blasetto J, et al. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother 2007;5:185-94
   PubMedGoogle Scholar
• Harley CR, Gandhi SK, Heien H, et al. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother 2008;9:669-76
   PubMed Web of Science ®Google Scholar
• Johns KW, Bennett MT, Bondy GP Are HIV positive patients resistant to statin therapy?. Lipids Health Dis 2007;6:27
   PubMedGoogle Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, et al. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Clin Ther 2007;29:2385-94
   PubMed Web of Science ®Google Scholar
• Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
   PubMed Web of Science ®Google Scholar